329 related articles for article (PubMed ID: 23377801)
1. The association between lysosomal protein glucocerebrosidase and Parkinson's disease.
Kong B; Yang T; Gu JW; Kuang YQ; Cheng L; Yang WT; Yang XK; Xia X; Cheng JM; Ma Y; Zhang JH; Yu SX
Eur Rev Med Pharmacol Sci; 2013 Jan; 17(2):143-51. PubMed ID: 23377801
[TBL] [Abstract][Full Text] [Related]
2. Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease.
Taguchi YV; Liu J; Ruan J; Pacheco J; Zhang X; Abbasi J; Keutzer J; Mistry PK; Chandra SS
J Neurosci; 2017 Oct; 37(40):9617-9631. PubMed ID: 28847804
[TBL] [Abstract][Full Text] [Related]
3. Plasma oligomeric alpha-synuclein is associated with glucocerebrosidase activity in Gaucher disease.
Nuzhnyi E; Emelyanov A; Boukina T; Usenko T; Yakimovskii A; Zakharova E; Pchelina S
Mov Disord; 2015 Jun; 30(7):989-91. PubMed ID: 25962734
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation.
Fishbein I; Kuo YM; Giasson BI; Nussbaum RL
Brain; 2014 Dec; 137(Pt 12):3235-47. PubMed ID: 25351739
[TBL] [Abstract][Full Text] [Related]
5. Silencing of Glucocerebrosidase Gene in
Abul Khair SB; Dhanushkodi NR; Ardah MT; Chen W; Yang Y; Haque ME
Front Neurosci; 2018; 12():81. PubMed ID: 29503608
[No Abstract] [Full Text] [Related]
6. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
[TBL] [Abstract][Full Text] [Related]
7. Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein.
Uemura N; Koike M; Ansai S; Kinoshita M; Ishikawa-Fujiwara T; Matsui H; Naruse K; Sakamoto N; Uchiyama Y; Todo T; Takeda S; Yamakado H; Takahashi R
PLoS Genet; 2015 Apr; 11(4):e1005065. PubMed ID: 25835295
[TBL] [Abstract][Full Text] [Related]
8. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
[TBL] [Abstract][Full Text] [Related]
9. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
[TBL] [Abstract][Full Text] [Related]
10. Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Papadopoulos VE; Nikolopoulou G; Antoniadou I; Karachaliou A; Arianoglou G; Emmanouilidou E; Sardi SP; Stefanis L; Vekrellis K
Hum Mol Genet; 2018 May; 27(10):1696-1710. PubMed ID: 29547959
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism.
Yun SP; Kim D; Kim S; Kim S; Karuppagounder SS; Kwon SH; Lee S; Kam TI; Lee S; Ham S; Park JH; Dawson VL; Dawson TM; Lee Y; Ko HS
Mol Neurodegener; 2018 Jan; 13(1):1. PubMed ID: 29310663
[TBL] [Abstract][Full Text] [Related]
12. Gaucher-Associated Parkinsonism.
Li Y; Li P; Liang H; Zhao Z; Hashimoto M; Wei J
Cell Mol Neurobiol; 2015 Aug; 35(6):755-61. PubMed ID: 25820783
[TBL] [Abstract][Full Text] [Related]
13. Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
Sardi SP; Viel C; Clarke J; Treleaven CM; Richards AM; Park H; Olszewski MA; Dodge JC; Marshall J; Makino E; Wang B; Sidman RL; Cheng SH; Shihabuddin LS
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):2699-2704. PubMed ID: 28223512
[TBL] [Abstract][Full Text] [Related]
14. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of α-synuclein simultaneously increases glutamate NMDA receptor phosphorylation and reduces glucocerebrosidase activity.
Yang J; Hertz E; Zhang X; Leinartaité L; Lundius EG; Li J; Svenningsson P
Neurosci Lett; 2016 Jan; 611():51-8. PubMed ID: 26610904
[TBL] [Abstract][Full Text] [Related]
16. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
Gegg ME; Verona G; Schapira AHV
Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
[TBL] [Abstract][Full Text] [Related]
17. [GBA mutations and Parkinson's disease].
Wang DX; Xie JX; Song N
Sheng Li Xue Bao; 2018 Jun; 70(3):294-300. PubMed ID: 29926071
[TBL] [Abstract][Full Text] [Related]
18. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains.
Gegg ME; Burke D; Heales SJ; Cooper JM; Hardy J; Wood NW; Schapira AH
Ann Neurol; 2012 Sep; 72(3):455-63. PubMed ID: 23034917
[TBL] [Abstract][Full Text] [Related]
19. Glucocerebrosidase haploinsufficiency in A53T α-synuclein mice impacts disease onset and course.
Tayebi N; Parisiadou L; Berhe B; Gonzalez AN; Serra-Vinardell J; Tamargo RJ; Maniwang E; Sorrentino Z; Fujiwara H; Grey RJ; Hassan S; Blech-Hermoni YN; Chen C; McGlinchey R; Makariou-Pikis C; Brooks M; Ginns EI; Ory DS; Giasson BI; Sidransky E
Mol Genet Metab; 2017 Dec; 122(4):198-208. PubMed ID: 29173981
[TBL] [Abstract][Full Text] [Related]
20. Advances in GBA-associated Parkinson's disease--Pathology, presentation and therapies.
Barkhuizen M; Anderson DG; Grobler AF
Neurochem Int; 2016 Feb; 93():6-25. PubMed ID: 26743617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
